Bacteria against cancer

With leading Oncology Professor, Dr. Angus Dalgleish.

(00:00)

Introduction to Mycobacterium vaccae (VAKI): Originally discovered by researchers (Graham Rook, John Stanford, John Grange), aiming to develop something better than BCG (tuberculosis vaccine). VAKI came from cow dung and showed strong immune-stimulating properties.

(02:00)

Cancer Vaccines & Tumor Resistance: Traditional cancer vaccines that target specific antigens often fail because tumors mutate. By contrast, boosting the innate (cell-mediated) immune response can circumvent such resistance.

(04:43)

Th1/Th2 Imbalance in Disease: In conditions like HIV, TB, and cancer, the Th1 (cell-mediated) side is suppressed, while Th2 (antibody/inflammatory) dominates. VAKI helps restore this balance by stimulating Th1 responses, which is crucial for attacking cancer cells.

(07:07)

Synergy with Modern Immunotherapies: Checkpoint inhibitors in melanoma, lung, and other cancers only work well when innate immunity (e.g., natural killer cells) is activated. Administering VAKI first can nearly double response rates, with minimal side effects.

(10:18)

Shift from VAKI to OBN: OBN is a “twin cousin” of VAKI, simpler to manufacture but similarly effective. The company producing it (Immodulon) ran into funding issues—despite FDA approvals and ongoing clinical trials, they are now in administration.

(15:26)

Pre-Surgery Immune Boost: Surgeons noted patients who received VAKI/OBN before operations recovered faster and had fewer metastases. Major surgeries often suppress immunity, so priming with these bacterial preparations helps maintain immune defenses.

(26:08)

Combining with Vitamin D & Low-Dose Naltrexone: Correcting vitamin D deficiency and adding low-dose naltrexone can further enhance innate immunity and reduce inflammation. This synergy makes standard treatments (chemotherapy, radiotherapy) more effective, often at lower doses.

(37:10)

Prophylactic Potential & Regulatory Frustrations: Annual or biannual shots of OBN (from around age 55) could theoretically reduce cancer incidence and improve general immunity. However, regulatory hurdles, big pharmaceutical disinterest, and funding shortfalls have stalled widespread availability.

(48:04)

Call for Investors/Entrepreneurs: With the manufacturer in administration, there is an urgent need for backers to purchase and continue the production process. All regulatory groundwork and trial approvals are in place, making it a “bargain basement” opportunity.

(55:38)

Concluding Frustration: Speakers lament the bureaucracy and lack of “common sense” in healthcare regulation. They emphasize that a safe, low-cost, broadly effective immune-boosting therapy risks being lost due to financial and regulatory barriers rather than scientific or clinical failures.